헬스케어 수탁 개발 및 제조 기관 시장 : 서비스 내용별, 분자 유형별, 제형별, 용도별, 치료 영역별, 최종사용자별 - 세계 예측(2025-2030년)

The Healthcare Contract Development & Manufacturing Organization Market was valued at USD 331.99 billion in 2024 and is projected to grow to USD 360.38 billion in 2025, with a CAGR of 8.92%, reaching USD 554.39 billion by 2030.

Unlocking the Foundations of the Healthcare CDMO Ecosystem Through Innovative Collaboration and Strategic Development Pathways

In the rapidly evolving world of healthcare contract development and manufacturing, stakeholders are navigating a complex blend of scientific innovation, regulatory demands, and strategic partnerships. The convergence of specialized expertise and advanced technology is reshaping how therapeutic candidates move from concept to commercialization. As biopharmaceutical pipelines continue to expand, CDMOs are increasingly pivotal in providing scalable solutions that address the intricacies of clinical trials, process development, and large-scale production. These organizations now serve as vital catalysts for bringing new treatments to market with greater efficiency and integrity.

Moreover, the integration of digital platforms and automation is driving operational excellence across preclinical and clinical stages. This trend underscores a shift toward streamlined workflows that reduce cycle times while ensuring strict adherence to regulatory frameworks. In addition, global supply chain complexity demands that CDMOs not only demonstrate technical prowess but also exhibit robust quality management systems and adaptive risk mitigation strategies. Consequently, an in-depth understanding of these multifaceted drivers is essential for decision-makers seeking to align their development agendas with evolving industry benchmarks.

Furthermore, strategic collaborations between pharmaceutical companies and specialized service providers are fostering an environment of co-innovation. Through these alliances, clients benefit from tailored solutions that span API synthesis, formulation development, and finished dosage manufacturing. This tailored approach supports the advancement of personalized medicine, enabling more targeted therapies to reach patients faster. Collaborative project governance models and joint risk-sharing agreements further enhance alignment between sponsors and service partners.

In addition, scrutiny over development costs and pressure to optimize margins compel CDMOs to refine financial models and operational workflows. Emphasis on lean manufacturing approaches and modular facility designs helps contain capital expenditures while enabling capacity scalability. Complementary bioanalytical services and regulatory intelligence offerings empower clients to navigate complex approval processes with greater confidence.

Finally, global health imperatives, such as pandemic preparedness and equitable vaccine distribution, have underscored the critical role of agile manufacturing networks. CDMOs are being called upon to pivot rapidly, repurpose existing assets, and support emergency response initiatives. These collective forces establish a dynamic foundation for the CDMO ecosystem, setting the stage for a deeper exploration of the transformative trends and structural shifts that follow in this report.

Charting Transformative Shifts and Technological Disruptions Reshaping Contract Development and Manufacturing in the Healthcare Sector

Over the past decade, transformative shifts have redefined the healthcare CDMO landscape, driven by digitalization, novel modalities, and evolving regulatory paradigms. The adoption of artificial intelligence and machine learning in drug discovery and process optimization has accelerated lead selection and enhanced predictive modeling. As a result, CDMOs are harnessing AI to streamline manufacturing workflows, anticipate quality deviations, and optimize resource allocation. These technological advancements are complemented by the rise of continuous manufacturing platforms, which offer enhanced throughput and superior process control compared to traditional batch methods.

In parallel, the industry is witnessing a surge of interest in cell and gene therapies, vaccines, and other complex biologics. This trend necessitates specialized expertise in upstream cell culture, vector production, and aseptic fill-finish processes. Consequently, CDMOs are expanding their capabilities to include single-use bioreactors, closed-system technologies, and modular cleanroom designs. Additionally, the strengthening of regulatory scrutiny around advanced therapies is prompting service providers to invest in robust compliance frameworks and data integrity solutions. As these modalities move from clinical proof-of-concept to commercial scale, the ability to navigate stringent regulatory pathways becomes a critical differentiator.

Moreover, supply chain resilience has emerged as a strategic priority. Events such as raw material shortages and global disruptions have underscored the need for diversified sourcing strategies and regional manufacturing footprints. In response, leading CDMOs are adopting risk-based approaches to supplier qualification and leveraging geographically dispersed facilities. This focus on agility ensures that clients benefit from uninterrupted production and accelerated timelines.

Notably, regulatory agencies are embracing digital submission portals and real-time data monitoring to expedite approvals and enhance traceability. This development compels CDMOs to adopt integrated data management systems and maintain transparent audit trails. Sustainability initiatives are also gaining momentum, driving interest in green manufacturing practices, single-use bioprocessing, and resource-efficient upstream and downstream processes. As environmental stewardship becomes a critical corporate responsibility, service providers must align their operational strategies with emerging global sustainability standards.

Equally important is the cultivation of specialized talent pools capable of operating next-generation manufacturing platforms. CDMOs are expanding their investment in workforce development programs, partnering with academic institutions and technical schools to ensure a pipeline of skilled professionals adept in advanced bioprocessing, quality sciences, and digital analytics. This emphasis on human capital underscores the industry's recognition that technological capabilities must be supported by specialized expertise to achieve long-term success.

Evaluating the Comprehensive Impact of 2025 United States Tariffs on Drug Development Services and Manufacturing Operations

The implementation of the United States tariffs in 2025 has introduced a new set of considerations for organizations engaged in contract development and manufacturing services. By imposing additional duties on critical raw materials, active pharmaceutical ingredients, and specialized equipment, these measures have reshaped cost structures and prompted strategic recalibrations. Contract development service providers are particularly sensitive to input cost fluctuations, as clinical and preclinical activities rely heavily on imported reagents and advanced analytical instruments. Consequently, clients and service partners alike are reevaluating supply agreements and exploring alternative sourcing to mitigate the financial impact.

As a result, contract manufacturing facilities that depend on cross-border trade for API intermediates and finished dosage equipment are experiencing increased operational expenses. This shift has spurred a reexamination of nearshoring and reshoring strategies, with many stakeholders considering domestic expansion to circumvent tariff-related costs. While localized manufacturing can enhance supply chain control and reduce lead times, it also requires significant investment in infrastructure and workforce development. Therefore, organizations must balance these capital commitments against the anticipated benefits of tariff avoidance and heightened regulatory certainty.

Furthermore, the tariffs have amplified the importance of strategic planning in procurement and production scheduling. Service providers are adopting dynamic tariff modeling tools to forecast duty implications and adjust contract terms accordingly. In addition, transparent dialogue between CDMOs and their clients is essential for aligning budgets and timelines under the new trade environment. Ultimately, the 2025 tariffs have not only affected bottom-line considerations but have also catalyzed a broader reassessment of globalization strategies within the healthcare manufacturing sector.

Moreover, the evolving tariff landscape is driving collaboration across stakeholders to develop cohesive mitigation strategies. Industry consortia and trade associations are engaging in dialogue with regulatory authorities to advocate for more predictable trade policies and exemptions for critical healthcare components. These collective efforts underscore the sector's resilience and commitment to ensuring uninterrupted access to life-saving therapies. As the tariff framework continues to evolve, the ability to anticipate and adapt to regulatory shifts will remain a defining attribute of successful contract development and manufacturing organizations.

In legal and contractual terms, clients are negotiating more flexible agreements that incorporate tariff fluctuation clauses and shared risk provisions. Some organizations have petitioned for tariff exclusions on critical healthcare supplies, underscoring the importance of regulatory advocacy. These developments highlight the need for continuous monitoring of trade policy shifts and proactive engagement with government stakeholders to secure favorable outcomes. As the tariff regime continues to evolve, the capacity to pivot quickly and restructure agreements will remain a competitive necessity.

Revealing Key Segmentation Insights Illuminating Service, Molecule, Dosage, Application, Therapeutic Area, and End User Dynamics

Segmentation insights reveal that the healthcare contract development and manufacturing market is intricately structured to address the diverse needs of clients across multiple service offerings, molecule types, dosage forms, therapeutic applications, and end-user categories. In terms of service offering, the market encompasses contract development services and contract manufacturing services. The former is further subdivided into clinical development, which comprises clinical trials support and regulatory support, and preclinical development, which spans in vitro and in vivo studies as well as toxicology studies. Contract manufacturing service offerings include active pharmaceutical ingredient manufacturing, finished dosage form manufacturing, medical device production, and packaging and labeling services, each catering to distinct phases of the product lifecycle.

When considering molecule type, the landscape is divided into large molecules and small molecules. Large molecule services are oriented toward monoclonal antibodies, recombinant proteins, and vaccines, reflecting the ongoing expansion of biologics and immunotherapies. Small molecule services continue to support traditional chemical entities, yet they benefit from novel formulation technologies that enhance bioavailability and stability. The market also segments by dosage form, addressing liquid, semi-solid, and solid dosage forms to meet therapeutic and administration preferences.

In addition, application-based segmentation highlights the differential demands of generic drugs, patented drugs, and medical devices. The generics sector emphasizes cost-efficiency and regulatory compliance, whereas the patented drug segment prioritizes innovation, intellectual property protection, and accelerated timelines. Medical device manufacturing services underscore precision engineering and stringent quality management. Therapeutic area segmentation spans cardiology, immunology, infectious diseases, metabolic disorders, neurology, and oncology, illustrating the varied complexity of therapeutic targets. Finally, end-user segmentation ranges from academic and research institutions and biotechnology companies to generic drug and medical device manufacturers, as well as pharmaceutical companies. The latter category differentiates between large pharmaceutical corporations and small and medium-sized enterprises, reflecting the spectrum of outsourcing requirements from early-stage research through commercial supply.

By leveraging this granular segmentation framework, service providers can tailor value propositions to meet the precise needs of each client segment, driving deeper engagement and fostering long-term partnerships. Furthermore, segmentation analytics can uncover under-served niches and inform strategic investment decisions in capacity expansion or capability development.

Uncovering Strategic Regional Dynamics Across the Americas, Europe Middle East Africa, and Asia Pacific Healthcare Manufacturing Corridors

Regional dynamics in the healthcare contract development and manufacturing sphere are shaped by unique regulatory frameworks, technological capabilities, and market maturity across the Americas, Europe Middle East Africa, and Asia Pacific. In the Americas, the United States leads with a robust CDMO infrastructure underpinned by stringent Food and Drug Administration regulations and a mature biotech ecosystem. Canada complements this landscape with specialized service providers and favorable trade agreements. These markets benefit from advanced clinical trial networks and well-established supply chains, facilitating rapid scale-up and market entry for innovative therapies.

In the Europe Middle East Africa region, the European pharmaceutical market is characterized by harmonized regulations through the European Medicines Agency and a strong emphasis on quality and safety. Key manufacturing hubs in Germany, Switzerland, and France drive high-tech biologic and small molecule production. Meanwhile, Middle Eastern economies are increasingly investing in pharmaceutical clusters to diversify their industrial base, and African markets present emerging opportunities in generic drug production and regulatory capacity building. This constellation of markets offers a blend of mature and developing landscapes, providing both stability and growth potential.

Asia Pacific has emerged as a critical manufacturing powerhouse, with China and India serving as predominant centers for active pharmaceutical ingredient synthesis and large-scale formulation. These countries are complemented by rapidly advancing capabilities in Japan, South Korea, and Australia, where regulatory modernization and digital innovation are accelerating service offerings. Given the region's cost advantages and expanding technical expertise, Asia Pacific remains a focal point for outsourcing strategies aimed at balancing efficiency, quality, and speed to market.

Moreover, free trade agreements such as USMCA and CPTPP influence regional supply chain configurations and incentivize cross-border collaborations. Regulatory harmonization efforts within regional blocs and the establishment of pan-regional clinical trial networks are further enhancing market access and operational flexibility. These developments underscore the importance of region-specific strategies that leverage local strengths while maintaining global consistency.

Profiling the Leading Industry Players Driving Innovation, Partnerships, and Competitive Advantage Within the Healthcare CDMO Environment

In an increasingly competitive CDMO environment, several leading companies are distinguishing themselves through strategic investments, technological advancement, and global footprint expansion. Catalent has reinforced its position by integrating advanced gene therapy capabilities and extending its clinical-to-commercial manufacturing services. Lonza has focused on expanding single-use bioreactor capacity and enhancing its cell and gene therapy platforms. Thermo Fisher Scientific continues to leverage its broad analytical instrumentation portfolio and digital process analytics to offer end-to-end solutions across development and manufacturing.

Samsung Biologics has rapidly grown its contract manufacturing capacity in Asia Pacific, emphasizing large-scale biologics production and robust quality systems. WuXi Biologics has differentiated itself through flexible capacity models and strategic partnerships in the immuno-oncology space. Emerging companies are also making their mark by specializing in niche areas, such as viral vector manufacturing, peptide synthesis, and high-potency APIs. These specialized providers are forming alliances with academic institutions and biotech startups to co-develop cutting-edge modalities, thereby expanding their service catalog.

Thermo Fisher Scientific's collaboration with digital analytics firms exemplifies the integration of process intelligence and predictive quality into service offerings. Similarly, Evonik has bolstered its peptide synthesis and lipid nanoparticle capabilities through strategic joint ventures, catering to mRNA delivery platforms. Mid-sized players such as AGC Biologics and Rentschler Biopharma are investing in flexible manufacturing lines and single-use technologies to respond rapidly to evolving client demands. These collective endeavors illustrate a trend toward networked innovation ecosystems, where technology partnerships and shared infrastructure accelerate capability development. As competition intensifies, the intersection of specialized expertise, strategic alliances, and digital enablement will define the next wave of market leaders.

Delivering Strategic and Actionable Recommendations to Navigate Complex Challenges and Seize Growth Opportunities in Healthcare Contract Development

Industry leaders seeking to capitalize on evolving opportunities within the healthcare CDMO sector must adopt strategic approaches that align operational excellence with client demands. To begin, investing in advanced digital platforms and data analytics capabilities will enhance process transparency and quality control, enabling providers to identify bottlenecks, predict maintenance needs, and optimize resource allocation. Such digitalization initiatives should be complemented by upskilling programs to ensure that personnel can effectively leverage these technologies.

In addition, forging deeper collaborations across the value chain is critical. Service providers should explore co-development partnerships with biotechnology firms and academic institutions to share risk, accelerate innovation, and access novel therapeutic pipelines. Similarly, establishing flexible contract frameworks that accommodate shifting project requirements and regulatory changes can foster stronger client relationships. As global supply chain vulnerabilities persist, diversifying sourcing strategies and establishing redundant supplier networks will mitigate disruptions and protect project timelines.

Furthermore, sustainability and regulatory efficiency are emerging as competitive differentiators. Companies should prioritize green chemistry and energy-efficient processes to address environmental concerns and regulatory pressures. Proactively engaging with regulatory authorities and participating in guideline development can streamline approval pathways and reinforce credibility.

Furthermore, prioritizing robust risk management frameworks, including scenario planning and stress-testing of supply chains, will enable organizations to anticipate potential disruptions and implement corrective actions swiftly. Embracing customer-centric resource allocation, such as adaptive project teams and dynamic capacity scheduling, can enhance service responsiveness. Companies should also consider portfolio rationalization to focus investments on high-growth therapeutic areas and high-value modalities, optimizing return on investment. Finally, integrating sustainability metrics into performance dashboards and pursuing certifications-such as ISO 14001 for environmental management-will resonate with clients and regulators alike, reinforcing a commitment to both quality and corporate responsibility.

Outlining the Robust and Transparent Methodological Framework Underpinning Our Comprehensive Healthcare CDMO Market Research Approach

Ensuring the validity and rigor of the insights presented requires a robust research methodology grounded in both qualitative and quantitative analysis. The process commences with comprehensive secondary research, leveraging peer-reviewed literature, regulatory documents, and company filings to map industry trends and technological advancements. This foundation is enriched through primary research, which includes in-depth interviews with key opinion leaders, industry executives, and technical experts to validate hypotheses and uncover nuanced perspectives.

Data triangulation is employed to cross-verify information from multiple sources, enhancing the reliability of findings. Custom surveys and structured questionnaires further quantify stakeholder priorities, challenges, and investment intentions. Competitive benchmarking offers comparative analyses of service provider capabilities, technological adoption rates, and geographical footprints. Throughout the research lifecycle, continuous feedback loops with subject matter experts ensure alignment with market realities and emerging developments.

Quantitative techniques, including statistical process control and multivariate data analysis, underpin the evaluation of process consistency and performance benchmarks. Scenario modeling and sensitivity analysis offer insights into how market variables, such as tariff fluctuations or regulatory changes, might influence industry trajectories. Technology adoption assessments evaluate readiness and scalability of emerging tools like continuous manufacturing and digital twins. All findings are peer-reviewed by an advisory panel comprising senior industry executives and regulatory specialists, ensuring that the report's conclusions withstand rigorous scrutiny. This methodological rigor provides stakeholders with a reliable foundation for strategic planning and investment decisions.

Synthesizing Key Findings and Strategic Insights to Conclude the Analysis of Healthcare Contract Development and Manufacturing Tendencies

Drawing together the myriad insights from this analysis, it is evident that the healthcare CDMO sector is at a pivotal juncture characterized by technological disruption, regulatory evolution, and shifting globalization strategies. Advanced modalities such as cell and gene therapies demand specialized manufacturing capabilities and stringent quality governance, while digitalization and automation are redefining process efficiency. The introduction of 2025 United States tariffs has further underscored the importance of agile supply chain strategies and strategic procurement planning.

Segmentation insights illuminate the multifaceted nature of service offerings, molecule types, dosage forms, therapeutic areas, and end-user requirements, highlighting the necessity for tailored solutions across each dimension. Regional dynamics in the Americas, Europe Middle East Africa, and Asia Pacific reveal divergent regulatory landscapes and growth trajectories, offering distinct opportunities for market entry and expansion. Leading companies are differentiating through strategic acquisitions, technology investments, and global capacity expansions, signaling a competitive environment driven by innovation and scalability.

Looking ahead, the convergence of digital biomanufacturing, real-time analytics, and integrated CDMO solutions presents a powerful opportunity to transcend traditional operational boundaries. Providers that master end-to-end digitized workflows and establish collaborative innovation platforms will unlock new efficiencies and accelerate time-to-market for complex therapies. Additionally, the potential for regional centers of excellence-paired with distributed manufacturing hubs-offers a blueprint for scalable and resilient supply networks. Ultimately, success will hinge on an organization's ability to balance technological advancement, regulatory compliance, and strategic adaptability in a fluid and competitive environment.

In sum, the synthesis of market drivers, segmentation frameworks, regional insights, and competitive dynamics underscores the multifaceted nature of the CDMO landscape. Organizations that integrate these perspectives into cohesive strategies will gain a sustainable advantage and contribute meaningfully to the future of healthcare innovation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Expansion of cell and gene therapy contract manufacturing capacity to meet rising demand
• 5.2. Adoption of continuous manufacturing technologies to improve biologics production efficiency
• 5.3. Integration of artificial intelligence and machine learning for predictive process control in CDMOs
• 5.4. Implementation of modular and flexible facility designs to accelerate product commercialization timelines
• 5.5. Shift towards outsourcing biosimilar development to specialized CDMOs for cost containment and speed
• 5.6. Focus on sustainability initiatives including green chemistry and waste reduction in CDMO operations
• 5.7. Strategic partnerships between biotech innovators and CDMOs for early-stage process development
• 5.8. Regulatory harmonization efforts influencing global quality standards in contract manufacturing of biologics
• 5.9. Adoption of digital supply chain platforms for real-time tracking and risk management in CDMO networks
• 5.10. Increasing investment in end-to-end contract development services to support personalized medicine pipelines

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Healthcare Contract Development & Manufacturing Organization Market, by Service Offering

• 8.1. Introduction
• 8.2. Contract Development Services
  • 8.2.1. Clinical Development
    • 8.2.1.1. Clinical Trials Support
    • 8.2.1.2. Regulatory Support
  • 8.2.2. Preclinical Development
    • 8.2.2.1. In Vitro & In Vivo Studies
    • 8.2.2.2. Toxicology Studies
  • 8.2.3. Process Development
• 8.3. Contract Manufacturing Services
  • 8.3.1. API Manufacturing
  • 8.3.2. Finished Dosage Form Manufacturing (FDF)
  • 8.3.3. Medical Device Manufacturing
  • 8.3.4. Packaging & Labeling

9. Healthcare Contract Development & Manufacturing Organization Market, by Molecule Type

• 9.1. Introduction
• 9.2. Large Molecules
  • 9.2.1. Monoclonal Antibodies
  • 9.2.2. Recombinant Proteins
  • 9.2.3. Vaccines
• 9.3. Small Molecules

10. Healthcare Contract Development & Manufacturing Organization Market, by Dosage Form

• 10.1. Introduction
• 10.2. Liquid Dosage Forms
• 10.3. Semi-Solid Dosage Forms
• 10.4. Solid Dosage Forms

11. Healthcare Contract Development & Manufacturing Organization Market, by Application

• 11.1. Introduction
• 11.2. Generic Drugs
• 11.3. Medical Devices
• 11.4. Patented Drugs

12. Healthcare Contract Development & Manufacturing Organization Market, by Therapeutic Area

• 12.1. Introduction
• 12.2. Cardiology
• 12.3. Immunology
• 12.4. Infectious Disease
• 12.5. Metabolic Disorders
• 12.6. Neurology
• 12.7. Oncology

13. Healthcare Contract Development & Manufacturing Organization Market, by End User

• 13.1. Introduction
• 13.2. Academic & Research Institutions
• 13.3. Biotechnology Companies
• 13.4. Generic Drug Manufacturers
• 13.5. Medical Device Companies
• 13.6. Pharmaceutical Companies
  • 13.6.1. Big Pharmaceutical Companies
  • 13.6.2. Small & Medium-sized Pharmaceutical Companies

14. Americas Healthcare Contract Development & Manufacturing Organization Market

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. Argentina

15. Europe, Middle East & Africa Healthcare Contract Development & Manufacturing Organization Market

• 15.1. Introduction
• 15.2. United Kingdom
• 15.3. Germany
• 15.4. France
• 15.5. Russia
• 15.6. Italy
• 15.7. Spain
• 15.8. United Arab Emirates
• 15.9. Saudi Arabia
• 15.10. South Africa
• 15.11. Denmark
• 15.12. Netherlands
• 15.13. Qatar
• 15.14. Finland
• 15.15. Sweden
• 15.16. Nigeria
• 15.17. Egypt
• 15.18. Turkey
• 15.19. Israel
• 15.20. Norway
• 15.21. Poland
• 15.22. Switzerland

16. Asia-Pacific Healthcare Contract Development & Manufacturing Organization Market

• 16.1. Introduction
• 16.2. China
• 16.3. India
• 16.4. Japan
• 16.5. Australia
• 16.6. South Korea
• 16.7. Indonesia
• 16.8. Thailand
• 16.9. Philippines
• 16.10. Malaysia
• 16.11. Singapore
• 16.12. Vietnam
• 16.13. Taiwan

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Baxter International, Inc.
  • 17.3.2. Boehringer Ingelheim International GmbH
  • 17.3.3. Cambrex Corporation
  • 17.3.4. Catalent Inc.
  • 17.3.5. Charles River Laboratories International, Inc.
  • 17.3.6. Corden Pharma International GmbH
  • 17.3.7. Curia Global, Inc.
  • 17.3.8. Eurofins Scientific SE
  • 17.3.9. EVER company group
  • 17.3.10. Evonik Industries AG
  • 17.3.11. FUJIFILM Diosynth Biotechnologies
  • 17.3.12. Jabil, Inc.
  • 17.3.13. Lonza Group AG
  • 17.3.14. MedPharm Ltd.
  • 17.3.15. Merck KGaA
  • 17.3.16. NextPharma GmbH
  • 17.3.17. Piramal Group
  • 17.3.18. Porton Pharma Solutions Ltd
  • 17.3.19. Recipharm AB
  • 17.3.20. Samsung Biologics
  • 17.3.21. Sanmina Corporation
  • 17.3.22. Siegfried Holding AG
  • 17.3.23. Siegfried-Group
  • 17.3.24. Thermo Fisher Scientific, Inc.
  • 17.3.25. WuXi AppTec

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix